Cabozantinib, a MET inhibitor that targets several tyrosine kinase receptors, such as VEGFR, c-MET, and AXL is being studied in conjunction with pembrolizumab, a humanized immunoglobulin that acts against PD-1, this combination is also being studied in a phase I/II clinical trial in patients with advanced metastatic melanoma (NCT03957551). Here, MET is linked to metastatic melanoma.